221 related articles for article (PubMed ID: 24347427)
1. Mass-array screening of frequent mutations in cancers reveals RB1 alterations in aggressive adrenocortical carcinomas.
Ragazzon B; Libé R; Assié G; Tissier F; Barreau O; Houdayer C; Perlemoine K; Audebourg A; Clauser E; René-Corail F; Bertagna X; Dousset B; Bertherat J; Groussin L
Eur J Endocrinol; 2014 Mar; 170(3):385-91. PubMed ID: 24347427
[TBL] [Abstract][Full Text] [Related]
2. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers.
Ragazzon B; Libé R; Gaujoux S; Assié G; Fratticci A; Launay P; Clauser E; Bertagna X; Tissier F; de Reyniès A; Bertherat J
Cancer Res; 2010 Nov; 70(21):8276-81. PubMed ID: 20959480
[TBL] [Abstract][Full Text] [Related]
3. Integrated genomic characterization of adrenocortical carcinoma.
Assié G; Letouzé E; Fassnacht M; Jouinot A; Luscap W; Barreau O; Omeiri H; Rodriguez S; Perlemoine K; René-Corail F; Elarouci N; Sbiera S; Kroiss M; Allolio B; Waldmann J; Quinkler M; Mannelli M; Mantero F; Papathomas T; De Krijger R; Tabarin A; Kerlan V; Baudin E; Tissier F; Dousset B; Groussin L; Amar L; Clauser E; Bertagna X; Ragazzon B; Beuschlein F; Libé R; de Reyniès A; Bertherat J
Nat Genet; 2014 Jun; 46(6):607-12. PubMed ID: 24747642
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers.
Gaujoux S; Pinson S; Gimenez-Roqueplo AP; Amar L; Ragazzon B; Launay P; Meatchi T; Libé R; Bertagna X; Audebourg A; Zucman-Rossi J; Tissier F; Bertherat J
Clin Cancer Res; 2010 Nov; 16(21):5133-41. PubMed ID: 20978149
[TBL] [Abstract][Full Text] [Related]
5. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations.
Durand J; Lampron A; Mazzuco TL; Chapman A; Bourdeau I
J Clin Endocrinol Metab; 2011 Jul; 96(7):E1206-11. PubMed ID: 21565795
[TBL] [Abstract][Full Text] [Related]
6. Wnt/beta-catenin and 3',5'-cyclic adenosine 5'-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors.
Gaujoux S; Tissier F; Groussin L; Libé R; Ragazzon B; Launay P; Audebourg A; Dousset B; Bertagna X; Bertherat J
J Clin Endocrinol Metab; 2008 Oct; 93(10):4135-40. PubMed ID: 18647815
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of adrenocortical cancer.
Bertherat J; Bertagna X
Best Pract Res Clin Endocrinol Metab; 2009 Apr; 23(2):261-71. PubMed ID: 19500768
[TBL] [Abstract][Full Text] [Related]
8. Wnt/β-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice.
Borges KS; Pignatti E; Leng S; Kariyawasam D; Ruiz-Babot G; Ramalho FS; Taketo MM; Carlone DL; Breault DT
Oncogene; 2020 Jul; 39(30):5282-5291. PubMed ID: 32561853
[TBL] [Abstract][Full Text] [Related]
9. Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma.
Juhlin CC; Goh G; Healy JM; Fonseca AL; Scholl UI; Stenman A; Kunstman JW; Brown TC; Overton JD; Mane SM; Nelson-Williams C; Bäckdahl M; Suttorp AC; Haase M; Choi M; Schlessinger J; Rimm DL; Höög A; Prasad ML; Korah R; Larsson C; Lifton RP; Carling T
J Clin Endocrinol Metab; 2015 Mar; 100(3):E493-502. PubMed ID: 25490274
[TBL] [Abstract][Full Text] [Related]
10. Investigation of N-cadherin/β-catenin expression in adrenocortical tumors.
Rubin B; Regazzo D; Redaelli M; Mucignat C; Citton M; Iacobone M; Scaroni C; Betterle C; Mantero F; Fassina A; Pezzani R; Boscaro M
Tumour Biol; 2016 Oct; 37(10):13545-13555. PubMed ID: 27468715
[TBL] [Abstract][Full Text] [Related]
11. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors.
Tissier F; Cavard C; Groussin L; Perlemoine K; Fumey G; Hagneré AM; René-Corail F; Jullian E; Gicquel C; Bertagna X; Vacher-Lavenu MC; Perret C; Bertherat J
Cancer Res; 2005 Sep; 65(17):7622-7. PubMed ID: 16140927
[TBL] [Abstract][Full Text] [Related]
12. Sarcomatoid adrenocortical carcinoma: a comprehensive pathological, immunohistochemical, and targeted next-generation sequencing analysis.
Papathomas TG; Duregon E; Korpershoek E; Restuccia DF; van Marion R; Cappellesso R; Sturm N; Rossi G; Coli A; Zucchini N; Stoop H; Oosterhuis W; Ventura L; Volante M; Fassina A; Dinjens WN; Papotti M; de Krijger RR
Hum Pathol; 2016 Dec; 58():113-122. PubMed ID: 27589897
[TBL] [Abstract][Full Text] [Related]
13. The genetics of adrenocortical tumors.
Espiard S; Bertherat J
Endocrinol Metab Clin North Am; 2015 Jun; 44(2):311-34. PubMed ID: 26038203
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of TP53 alterations in adrenocortical carcinomas.
Waldmann J; Patsalis N; Fendrich V; Langer P; Saeger W; Chaloupka B; Ramaswamy A; Fassnacht M; Bartsch DK; Slater EP
Langenbecks Arch Surg; 2012 Feb; 397(2):209-16. PubMed ID: 22203015
[TBL] [Abstract][Full Text] [Related]
15. Molecular markers and the pathogenesis of adrenocortical cancer.
Soon PS; McDonald KL; Robinson BG; Sidhu SB
Oncologist; 2008 May; 13(5):548-61. PubMed ID: 18515740
[TBL] [Abstract][Full Text] [Related]
16. Molecular screening for a personalized treatment approach in advanced adrenocortical cancer.
De Martino MC; Al Ghuzlan A; Aubert S; Assié G; Scoazec JY; Leboulleux S; Do Cao C; Libè R; Nozières C; Lombès M; Pattou F; Borson-Chazot F; Hescot S; Mazoyer C; Young J; Borget I; Colao A; Pivonello R; Soria JC; Bertherat J; Schlumberger M; Lacroix L; Baudin E
J Clin Endocrinol Metab; 2013 Oct; 98(10):4080-8. PubMed ID: 23979958
[TBL] [Abstract][Full Text] [Related]
17. Molecular basis of adrenocortical carcinomas.
Soon PS; Sidhu SB
Minerva Endocrinol; 2009 Jun; 34(2):137-47. PubMed ID: 19471238
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.
Wasserman JD; Novokmet A; Eichler-Jonsson C; Ribeiro RC; Rodriguez-Galindo C; Zambetti GP; Malkin D
J Clin Oncol; 2015 Feb; 33(6):602-9. PubMed ID: 25584008
[TBL] [Abstract][Full Text] [Related]
19. The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study.
Guerini-Rocco E; Hodi Z; Piscuoglio S; Ng CK; Rakha EA; Schultheis AM; Marchiò C; da Cruz Paula A; De Filippo MR; Martelotto LG; De Mattos-Arruda L; Edelweiss M; Jungbluth AA; Fusco N; Norton L; Weigelt B; Ellis IO; Reis-Filho JS
J Pathol; 2015 Oct; 237(2):166-78. PubMed ID: 26011570
[TBL] [Abstract][Full Text] [Related]
20. TP53 germline mutations in adult patients with adrenocortical carcinoma.
Herrmann LJ; Heinze B; Fassnacht M; Willenberg HS; Quinkler M; Reisch N; Zink M; Allolio B; Hahner S
J Clin Endocrinol Metab; 2012 Mar; 97(3):E476-85. PubMed ID: 22170717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
